A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Items 101–200 of 602
Yin, Z.-G., Zhang, J.-B., Kan, S.-L., & Wang, X.-G. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b8.28998 · Cited by 77
Nathavitharana, R. R., Hillemann, D., Schumacher, S. G., Schlueter, B., Ismail, N. A., Omar, S. V., Sikhondze, W., Havumaki, J., Valli, E., Boehme, C. C., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00251-16 · Cited by 75
Blueberry-Enriched Diet Protects Rat Heart from Ischemic Damage
Ahmet, I., Spangler, E. L., Shukitt‐Hale, B., Juhaszova, M., Sollott, S. J., Joseph, J. A., Ingram, D. K., & Talan, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005954 · Cited by 75
“The former is targeted through changing life style and diet, leading to reduction of cholesterol and other risk factors, strategies whose arsenal was recently expanded by using pharmacological tools such as statins [33–35].”
BackgroundAnticancer effects of silver nanoparticles encapsulated by Taxus baccata extracts
Kajani, A. A., Zarkesh‐Esfahani, S. H., Bordbar, A., Khosropour, A. R., Razmjou, A., & Kardi, M. T. (2016) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2016.08.064 · Cited by 75
Alberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2012) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcr158 · Cited by 66
Weight Loss Surgery for Mild to Moderate Obesity: A Systematic Review and Economic Evaluation
Picot, J., Jones, J., Colquitt, J. L., Loveman, E., & Clegg, A. J. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0679-z · Cited by 73
“[34] 1502 OBES SURG (2012) 22:1496–1506”
Fluvastatin for lowering lipids
Adams, S. P., Sekhon, S. S., Tsang, M., & Wright, J. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012282.pub2 · Cited by 72
Holtz, K. A., Kokotilo, K. J., Fitzgerald, B. E., & Frank, E. (2013) · Europe PMC (PubMed Central) · Cited by 72
Stacy, J. N., Schwartz, S. M., Ershoff, D., & Shreve, M. S. (2009) · Population Health Management · doi:10.1089/pop.2008.0046 · Cited by 63
Pickhardt, P. J., Correale, L., & Hassan, C. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03800-9 · Cited by 67
“assigned to moderate statin therapy, which was modeled as providing a mean 35% relative reduction in CV risk [24, 25].”
MethodDunn, A. C. (2012) · American Economic Journal Applied Economics · doi:10.1257/app.4.3.167 · Cited by 67
“The U.K. study by Ward et al. (2007) and the Heart Protection Study Collaboration Group (2010) provide nice reviews of the literature looking at statin drug e¤ectiveness.”
BackgroundPerera, R., McFadden, E., McLellan, J., Lung, T., Clarke, P., Pérez, T., Fanshawe, T., Dalton, A., Farmer, A., Glasziou, P., et al. (2015) · Health Technology Assessment · doi:10.3310/hta191000 · Cited by 62
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Can psychedelic compounds play a part in drug dependence therapy?
Sessa, B., & Johnson, M. W. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148031 · Cited by 57
Chiang, C.-E., Ferrières, J., Gotcheva, N. N., Raal, F. J., Shehab, A., Sung, J., Henriksson, K. M., & Hermans, M. P. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31179 · Cited by 63
Is brief advice in primary care a cost-effective way to promote physical activity?
Anokye, N. K., Lord, J., & Fox-Rushby, J. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2013-092897 · Cited by 64
Pons‐Rejraji, H., Brugnon, F., Sion, B., Maqdasy, S., Gouby, G., Pereira, B., Marceau, G., Grémeau, A., Drevet, J. R., Grizard, G., et al. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-65 · Cited by 64
“Statins are first-choice cholesterol lowering agents [1,3,4].”
Hovingh, G. K., Gandra, S. R., McKendrick, J., Dent, R. E., Wieffer, H., Catapano, A. L., OH, P. I., Rosenson, R. S., & Stroes, E. S. G. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.015 · Cited by 64
Burri, H., Sticherling, C., Wright, D., Makino, K., Smala, A. M., & Tilden, D. (2013) · EP Europace · doi:10.1093/europace/eut070 · Cited by 62
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
Lamond, N. W. D., Skedgel, C. D., Rayson, D., Lethbridge, L. N., & Younis, T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1989-5 · Cited by 61
Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis
Christopher, D. J., Schumacher, S. G., Michael, J. S., Luo, R., Balamugesh, T., Duraikannan, P., Pollock, N. R., Pai, M., & Denkinger, C. M. (2013) · European Respiratory Journal · doi:10.1183/09031936.00103213 · Cited by 60
Martin, N. K., Pitcher, A., Vickerman, P. T., Vassall, A., & Hickman, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022309 · Cited by 60
The Many Roles of Statins in Ischemic Stroke
Zhao, J., Zhang, X., Dong, L., Wen, Y., & Cui, L. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140923210929 · Cited by 61
“Statins have also been proved to significantly decrease cardiovascular risk and to improve clinical outcome [8].”
BackgroundSolomon, M. D., Leong, T. K., Levin, E. G., Rana, J. S., Jaffe, M. G., Sidney, S., Sung, S. H., Lee, C., DeMaria, A. N., & Go, A. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014415 · Cited by 60
Liu, S., Bertl, K., Sun, H., Liu, Z., Andrukhov, O., & Rausch‐Fan, X. (2012) · Human Cell · doi:10.1007/s13577-011-0028-x · Cited by 59
Featherstone, R. L., Dobson, J., Ederle, J., Doig, D., Bonati, L. H., Stephen Morris, A., Patel, N. V., & Brown, M. M. (2016) · Health Technology Assessment · doi:10.3310/hta20200 · Cited by 59
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Dehmer, S. P., Maciosek, M. V., LaFrance, A. B., & Flottemesch, T. J. (2017) · The Annals of Family Medicine · doi:10.1370/afm.2015 · Cited by 59
Robinson, Y., Sandén, B., & Olerud, C. (2013) · Patient Safety in Surgery · doi:10.1186/1754-9493-7-2 · Cited by 58
Ratnarajan, G., Newsom, W., Vernon, S. A., Fenerty, C., Henson, D. B., Spencer, A. F., Wang, Y., Harper, R. A., McNaught, A. I., Collins, L., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002715 · Cited by 58
Anchah, L., Hassali, M. A., Lim, M. S. H., Ibrahim, M. I. M., Sim, K. H., & Ong, T. K. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0583-7 · Cited by 58
Whyte, S., Cooper, K. L., Stevenson, M., Madan, J., & Akehurst, R. L. (2011) · Value in Health · doi:10.1016/j.jval.2010.10.037 · Cited by 58
Potential savings without compromising the quality of care
Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F. N., & Wettermark, B. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02129.x · Cited by 57
Raine, R., Wong, W., Ambler, G., Hardoon, S. L., Petersen, I., Morris, R. W., Bartley, M., & Blane, D. (2009) · BMJ · doi:10.1136/bmj.b1279 · Cited by 57
Matthan, N. R., Resteghini, N. A., Robertson, M., Ford, I., Shepherd, J., Packard, C. J., Buckley, B. M., Jukema, J. W., Lichtenstein, A. H., & Schaefer, E. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900032-jlr200 · Cited by 57
van Santen, D. K., de Vos, A. S., Matser, A. A., Willemse, S. B., Lindenburg, K., Kretzschmar, M., Prins, M., & de Wit, G. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163488 · Cited by 56
Beyhaghi, H., & Viera, A. J. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.11715 · Cited by 55
Scosyrev, E., Tobis, S., Donsky, H., Wu, G., Joseph, J., Rashid, H. H., & Messing, E. M. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11527.x · Cited by 54
Ara, R., Pandor, A., Stevens, J., Rees, A., & Rafia, R. (2009) · Health Technology Assessment · doi:10.3310/hta13340 · Cited by 54
Self-citationZhou, J., Wang, H., Zhang, H., Lutz, A. M., Tian, L., Hristov, D. H., & Willmann, J. K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3271 · Cited by 54
Mitchell, A. P., & Simpson, R. J. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-373 · Cited by 53
“Use of these drugs in additional low-risk patients may be, as our analysis suggests, a cost-effective intervention; however, this would require the dedication of significant health care resources [10].”
BackgroundBreeze, P. R., Thomas, C., Squires, H., Brennan, A., Greaves, C., Diggle, P. J., Brunner, E., Tabak, A., Preston, L., & Chilcott, J. (2017) · Diabetic Medicine · doi:10.1111/dme.13314 · Cited by 50
Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction
Thokala, P., Goodacre, S. W., Collinson, P. O., Stevens, J., Mills, N. L., Newby, D. E., Morris, F. A., Kendall, J., & Stevenson, M. (2012) · Heart · doi:10.1136/heartjnl-2012-302188 · Cited by 53
Mamakwa, S., Kahan, M., Kanate, D., Kirlew, M., Folk, D., Cirone, S., Rea, S., Parsons, P., Edwards, C., Gordon, J., et al. (2017) · Europe PMC (PubMed Central) · Cited by 53
Pfeil, A. M., Reich, O., Guerra, I., Cure, S., Negro, F., Müllhaupt, B., Lavanchy, D., & Schwenkglenks, M. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126984 · Cited by 51
Abdominal tuberculosis: a retrospective review of cases presenting to a UK district hospital
Mamo, J., Brij, S., & Enoch, D. (2013) · QJM · doi:10.1093/qjmed/hct003 · Cited by 51
McCann, P., Hogg, R. E., Wright, D. M., Pose-Bazarra, S., Chakravarthy, U., Pető, T., Cruise, S. M., McGuinness, B., Young, I. S., Kee, F., et al. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315330 · Cited by 50
Thermal characterization of lovastatin in pharmaceutical formulations
Yoshida, M. I., de Oliveira, M. A., Gomes, E. C. D. L., Mussel, W. D. N., Castro, W. V., & Soares, C. D. V. (2011) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-011-1510-0 · Cited by 50
“This results in premature atherosclerosis and in increased risk of cardiovascular disease, which is the major cause of morbidity and mortality around the globe [13–15].”
Backgroundvan der Burg, L. R. A., ter Wee, M. M., & Boonen, A. E. R. C. H. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201914 · Cited by 50
Labarthe, D. R., Goldstein, L. B., Antman, E. M., Arnett, D. K., Fonarow, G. C., Alberts, M. J., Hayman, L. L., Khera, A., Sallis, J. F., Daniels, S. R., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000410 · Cited by 49
Pourshahidi, L. K., Caballero, E., Osses, A., Hyland, B. W., Ternan, N. G., & Gill, C. I. R. (2020) · European Journal of Nutrition · doi:10.1007/s00394-019-02169-0 · Cited by 49
“The clinical benefits of lowering total and LDL cholesterol concentrations are well established [18, 19] given their role in the pathogenesis of coronary heart disease.”
BackgroundMistry, H., Morris, S., Dyer, M., Kotseva, K., Wood, D., & Buxton, M. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001029 · Cited by 48
Kuiper, J. G., Sanchez, R. J., Houben, E., Heintjes, E. M., Penning-van Beest, F. J. A., Khan, I., van Riemsdijk, M., & Herings, R. M. C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.001 · Cited by 48
For the Sake of Justice: Should We Prioritize Rare Diseases?
Juth, N. (2014) · Health Care Analysis · doi:10.1007/s10728-014-0284-5 · Cited by 47
Agrawal, R. V., González‐López, J. J., Cardoso, J., Gupta, B., Grant, R., Addison, P. K. F., Westcott, M. C., & Pavesio, C. E. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306474 · Cited by 47
Bhoyrul, B., Asfour, L., Lutz, G., Mitchell, L., Jerjen, R., Sinclair, R. D., Holmes, S., Chaudhry, I. H., & Harries, M. J. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3676 · Cited by 47
Geneletti, S., O’Keeffe, A. G., Sharples, L. D., Richardson, S. T., & Baio, G. (2015) · Statistics in Medicine · doi:10.1002/sim.6486 · Cited by 47
“For example, given extensive RCT literature [20], it is widely accepted that the effect of statin treatment is a decrease in LDL cholesterol of about 2 mmol/l.”
BackgroundVolpe, M., & Tocci, G. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000356766.86388.e5 · Cited by 46
Cziraky, M. J., Willey, V. J., McKenney, J. M., Kamat, S., Fisher, M. D., Guyton, J. R., Jacobson, T. A., & Davidson, M. H. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.06.006 · Cited by 45
Greenberg, J. D., Palmer, J. B., Li, Y., Herrera, V., Tsang, Y., & Liao, M. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150540 · Cited by 44
Barrios, V., Kaskens, L., Castellano, J. M., Cosín-Sales, J., Ruiz, J. E., Zsolt, I., Fuster, V., & Gracia, A. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.05.009 · Cited by 44
Johnston, S. C., Sidney, S., Hills, N. K., Grosvenor, D., Klingman, J. G., BERNSTEIN, A. L., & Levin, E. G. (2010) · Annals of Neurology · doi:10.1002/ana.22019 · Cited by 43
Poole, C., Smith, J. C., & Davies, J. S. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007910 · Cited by 43
“This is comparable to evaluations for the prevention of ischaemic heart disease with statin therapy.(27) Similarly, dominant QALY costs, (indicating that there are net savings accrued through fall prevention with vitamin D treatment), were noted with the application of the recommendations of the CMOs letter(8) for the…”
MethodHarris, T. J., Kerry, S., Victor, C. R., Iliffe, S., USSHER, M. H., Fox-Rushby, J. A., Whincup, P. H., Ekelund, U., Furness, C., Limb, E. S., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22370 · Cited by 42
Allonen, J., Nieminen, M. S., Lokki, M., Parkkonen, O., Vaara, S. M., Perola, M., Hiekkalinna, T., Strandberg, T. E., & Sinisalo, J. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22056 · Cited by 42
Eckhoff, L., Nielsen, M., Moeller, S., & Knoop, A. S. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.602111 · Cited by 42
Guthrie, B., Thompson, A., Dumbreck, S., Flynn, A., Alderson, P., Nairn, M., Treweek, S. P., & Payne, K. (2017) · Health Services and Delivery Research · doi:10.3310/hsdr05160 · Cited by 42
Kim, H., Chung, W., Cho, K. I., Kim, B., Seo, J.-S., Park, S., Kim, H. J., Lee, J., Kim, E. K., & Youn, H. (2018) · Journal of Cardiovascular Ultrasound · doi:10.4250/jcu.2018.26.1.1 · Cited by 42
Muntner, P., Mann, D., Wildman, R. P., Shimbo, D., Fuster, V., & Woodward, M. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.019 · Cited by 41
“The CHD and stroke risk reduction benefits were 26% (23%, 29%) and 16% (95% CI: 9%, 21%) for statins, 20% (12%, 27%) and 28% (19%, 36%) for ACE-inhibitors, 21% (8%, 31%) and 29% (19%, 37%) for lowdose diuretics, and 7% (0%, 19%) and 20% (4%, 34%) for beta-blockers(12-18).”
Statin Therapy in Rheumatoid Arthritis: A Cost-Effectiveness and Value-of-Information Analysis
Bansback, N. J., Ara, R., Ward, S. E., Anis, A. H., & Choi, H. K. (2009) · PharmacoEconomics · doi:10.2165/00019053-200927010-00004 · Cited by 41
Self-citationMansfield, L., Anokye, N., Fox-Rushby, J. A., & Kay, T. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009276 · Cited by 41
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
Conly, J., Clement, F. M., Tonelli, M. A., Hemmelgarn, B. R., Klarenbach, S. W., Lloyd, A. M., McAlister, F. A., Husereau, D., Wiebe, N., Au, F., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.101281 · Cited by 41
“However, whether statins are cost- effective in people at very low cardiovascular risk has been uncertain.(2,30) Some studies have suggested that their use in such people was associated with a cost per QALY gained of less than £20 000,(2) but only”
BackgroundBarrios, V., Kaskens, L., Castellano, J. M., Cosín-Sales, J., Ruiz, J. E., Zsolt, I., Fuster, V., & Gracia, A. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.05.011 · Cited by 41
Wallach‐Kildemoes, H., Vass, M., Hendriksen, C., & Andersen, M. T. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.08.008 · Cited by 40
Pitavastatin for lowering lipids
Adams, S. P., Alaeiilkhchi, N., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012735.pub2 · Cited by 40
Vegter, S., Oosterhof, P., van Boven, J. F. M., Stuurman-Bieze, A. G. G., Hiddink, E., & Postma, M. J. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.7.722 · Cited by 40
Gc, V. S., Suhrcke, M., Hardeman, W., Sutton, S. R., & Wilson, E. (2017) · Value in Health · doi:10.1016/j.jval.2017.07.005 · Cited by 40
“The annual costs associated with each health state were derived from previous studies [33, 36, 52-63].”
MethodNew American Heart Association/American College of Cardiology Guidelines on Cardiovascular Risk
MYERS, J. N. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.03.002 · Cited by 40
“In high-risk patients, lowcost (generic) statins have generally been considered to be cost-effective.(27,28) It remains unclear whether statin use is cost-effective for lower-risk groups, such as the broader population of individuals who might receive statins under the new guidelines.”
BackgroundPlosker, G. L., & Lyseng-Williamson, K. A. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725120-00005 · Cited by 40
Lipid lowering efficacy of rosuvastatin
Adams, S. P., & Wright, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010254 · Cited by 40
Salbach, N. M., Barclay, R., Webber, S. C., Jones, C., Mayo, N. E., Lix, L. M., Ripat, J. D., Grant, T. L., van Ineveld, C., & Chilibeck, P. D. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029393 · Cited by 39
Deep learning-assisted (automatic) diagnosis of glaucoma using a smartphone
Nakahara, K., Asaoka, R., Tanito, M., Shibata, N., Mitsuhashi, K., Fujino, Y., Matsuura, M., Inoue, T., Azuma, K., Obata, R., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318107 · Cited by 39
Screening for familial hypercholesterolaemia
Bender, R., Bell, D. A., Hooper, A. J., Edwards, G., BOCKXMEER, F. M. V., Watts, G. F., & Burnett, J. R. (2012) · Pathology · doi:10.1097/pat.0b013e32834efa07 · Cited by 39
Neumann, A., Maura, G., Weill, A., Ricordeau, P., Alla, F., & Allemand, H. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3544 · Cited by 38
García-Gil, M., Blanch, J., Comas‐Cufí, M., Daunis‐i‐Estadella, P., Bolíbar, B., Martí‐Lluch, R., Ponjoan, A., Alves‐Cabratosa, L., & Ramos, R. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.007 · Cited by 40
Universal antenatal screening for group B streptococcus may cause more harm than good
Seedat, F., Geppert, J., Stinton, C., Patterson, J. V., Freeman, K., Johnson, S. A., Fraser, H., Brown, C. S., Uthman, O. A., Tan, B. K., et al. (2019) · BMJ · doi:10.1136/bmj.l463 · Cited by 38
Meng, Y., Ward, S. E., Cooper, K. L., Harnan, S., & Wyld, L. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.10.001 · Cited by 38
Self-citationThick-tissue bioreactor as a platform for long-term organotypic culture and drug delivery
Markov, D. A., Lu, J. Q., Samson, P. C., Wikswo, J. P., & McCawley, L. J. (2012) · Lab on a Chip · doi:10.1039/c2lc40304h · Cited by 36
Plasencia, C., Kneepkens, E. L., Wolbink, G., Krieckaert, C. L. M., Turk, S. A., Navarro‐Compán, V., l'Ami, M. J., Nurmohamed, M. T., van der Horst-Bruinsma, I. E., Jurado, T., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141128 · Cited by 38
Statin use after intracerebral hemorrhage: a 10‐year nationwide cohort study
Tai, S., Lin, F., Lee, C., Chang, C., Wu, M., & Chien, C. (2016) · Brain and Behavior · doi:10.1002/brb3.487 · Cited by 38
“The benefits of HMG-CoA reductase inhibitors (statins) for the primary and secondary prevention of cardiac and cerebrovascular disease are adequately established (Amarenco et al. 2006; Gaspardone and Arca 2007; Ward et al. 2007).”
Afsar, N. A., Ufer, M., Haenisch, S., Remmler, C., Mateen, A., Usman, A., Ahmed, K. Z., Ahmad, H. R., & Cascorbi, I. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1134-0 · Cited by 37
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren
Ménard, J., & Azizi, M. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282ef45e9 · Cited by 37
Lipid lowering efficacy of atorvastatin
Wright, J. M., Adams, S. P., & Tsang, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226 · Cited by 37
Banach, M., Shekoohi, N., Mikhailidis, D. P., Lip, G. Y. H., Hernández, A. V., & Mazidi, M. (2022) · Archives of Medical Science · doi:10.5114/aoms/145970 · Cited by 36
Effecten van preventie. Deelrapport van de VTV 2010 Van gezond naar beter
van den Berg, M., & Schoemaker, C. (2010) · Rivm Repository (Netherlands National Institute for Public Health and the Environment) · Cited by 36
Jones, M., Tett, S. E., Peeters, G. M. E. E., Mishra, G. D., & Dobson, A. J. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0435-0 · Cited by 35
Liu, H.-C., Gao, Y.-L., Li, D., Zhao, X., Pan, Y., & Zhu, C. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02170-20 · Cited by 35
Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
Glueck, C. J., & Goldenberg, N. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3241 · Cited by 35
“Billions of dollars are spent on research and development of new therapies as well for the therapy itself to prevent both the risk of recurrent cardiovascular (CVD) events (secondary prevention) as well as preventing the fi rst event (primary prevention).(1,2) Ever since the connection between cholesterol levels and r…”
Jowett, S. M., Barton, P. M., Roalfe, A. K., Fletcher, K., Hobbs, R. F., McManus, R. J., & Mant, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182625 · Cited by 35
Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment
van Schoonhoven, A. V., van Asselt, A. D. I., Tomaszewski, M., Patel, P., Khunti, K., Gupta, P., & Postma, M. J. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11227 · Cited by 35
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.